Bridges Israel

Bridges Israel, headquartered in Tel Aviv, is the local affiliate of the Bridges impact investing platform, with a mandate to generate competitive financial returns alongside measurable social outcomes. The fund is organized around the conviction that impact and performance are not in tension, and its healthcare investments are shaped accordingly. Within the digital health and care delivery domain, Bridges Israel backs companies whose products improve access, affordability, or quality of care for underserved populations or whose business model produces measurable outcome improvements at scale.

The thesis applied to AI healthcare is straightforward. The fund favors software and tech-enabled services that demonstrably change cost, access, or clinical outcomes, with a preference for products that serve segments traditionally underserved by commercial healthcare. Mental health, chronic disease management, maternal and women’s health, primary care extension, and elder care are areas of natural fit. Pure enterprise infrastructure, biotech, and traditional medical devices are less central.

Check sizes range from $1M to $5M, typically deployed at seed, Series A, or early Series B. Bridges is willing to lead or co-lead and reserves capital for follow-on. Geography is centered on Israel, with companies expected to commercialize globally. The fund operates with explicit impact measurement frameworks, and portfolio companies should expect to articulate and track outcome metrics in addition to standard financial KPIs. That requirement is not bureaucratic theater. It shapes how the fund evaluates companies and how it supports them post-investment.

The team draws on the Bridges global network, combined with local Israeli investment and operational expertise. Investment partners participate at the board level and help portfolio companies navigate impact-linked reporting, payer strategy, and international expansion when relevant.

Founders should approach Bridges Israel with a coherent story about who is helped by the product, how that help can be measured, and why the business model produces both financial and social returns at scale. Introductions through Israeli VCs, impact investors elsewhere, or portfolio company founders are the most efficient path. The right time to engage is when the company has product-market fit signal, clear customer segments, and a working hypothesis on outcomes measurement. Founders unable or unwilling to operate within an impact reporting framework should look to generalist healthcare funds. Companies with no defensible link between business model and social outcome will struggle to clear diligence even if commercial metrics are strong. For founders building scalable digital health and care delivery models that meaningfully expand access or improve outcomes for underserved populations, Bridges Israel offers capital, discipline, and a global network of co-investors aligned around the same orientation.